BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33863935)

  • 1. Establishment and characterization of a new spontaneously immortalized ER
    Nobili S; Mannini A; Parenti A; Raggi C; Lapucci A; Chiorino G; Paccosi S; Di Gennaro P; Vezzosi V; Romagnoli P; Susini T; Coronnello M
    Sci Rep; 2021 Apr; 11(1):8340. PubMed ID: 33863935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables.
    Mohammadizadeh F; Naimi A; Rajabi P; Ghasemibasir H; Eftekhari A
    Indian J Med Sci; 2009 Apr; 63(4):152-62. PubMed ID: 19414985
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of CD44
    Chekhun VF; Lukianova NY; Chekhun SV; Bezdieniezhnykh NO; Zadvorniy TV; Borikun TV; Polishchuk LZ; Klyusov OМ
    Exp Oncol; 2017 Sep; 39(3):203-211. PubMed ID: 28967645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD44/CD24 as potential prognostic markers in node-positive invasive ductal breast cancer patients treated with adjuvant chemotherapy.
    Adamczyk A; Niemiec JA; Ambicka A; Mucha-Małecka A; Mituś J; Ryś J
    J Mol Histol; 2014 Feb; 45(1):35-45. PubMed ID: 23835592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
    Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD44+/CD24- phenotype contributes to malignant relapse following surgical resection and chemotherapy in patients with invasive ductal carcinoma.
    Lin Y; Zhong Y; Guan H; Zhang X; Sun Q
    J Exp Clin Cancer Res; 2012 Jul; 31(1):59. PubMed ID: 22762532
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.
    Bhat-Nakshatri P; Appaiah H; Ballas C; Pick-Franke P; Goulet R; Badve S; Srour EF; Nakshatri H
    BMC Cancer; 2010 Aug; 10():411. PubMed ID: 20691079
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of curcumin on the cell surface markers CD44 and CD24 in breast cancer.
    Calaf GM; Ponce-Cusi R; Abarca-Quinones J
    Oncol Rep; 2018 Jun; 39(6):2741-2748. PubMed ID: 29693159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
    Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
    Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nuclear beta-catenin and CD44 upregulation characterize invasive cell populations in non-aggressive MCF-7 breast cancer cells.
    Uchino M; Kojima H; Wada K; Imada M; Onoda F; Satofuka H; Utsugi T; Murakami Y
    BMC Cancer; 2010 Aug; 10():414. PubMed ID: 20696077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.
    Duru N; Fan M; Candas D; Menaa C; Liu HC; Nantajit D; Wen Y; Xiao K; Eldridge A; Chromy BA; Li S; Spitz DR; Lam KS; Wicha MS; Li JJ
    Clin Cancer Res; 2012 Dec; 18(24):6634-47. PubMed ID: 23091114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of Oncotype DX® recurrence score of paraffin-embedded core biopsy tissues in predicting response to neoadjuvant chemotherapy in women with breast cancer.
    Soran A; Bhargava R; Johnson R; Ahrendt G; Bonaventura M; Diego E; McAuliffe PF; Serrano M; Menekse E; Sezgin E; McGuire KP
    Breast Dis; 2016 Jul; 36(2-3):65-71. PubMed ID: 27662272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.
    Kinsella MD; Nassar A; Siddiqui MT; Cohen C
    Int J Clin Exp Pathol; 2012; 5(6):530-6. PubMed ID: 22949935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CD44+/CD24- phenotype is enriched in basal-like breast tumors.
    Honeth G; Bendahl PO; Ringnér M; Saal LH; Gruvberger-Saal SK; Lövgren K; Grabau D; Fernö M; Borg A; Hegardt C
    Breast Cancer Res; 2008; 10(3):R53. PubMed ID: 18559090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
    Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
    Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aromatase overexpression induces malignant changes in estrogen receptor α negative MCF-10A cells.
    Wang J; Gildea JJ; Yue W
    Oncogene; 2013 Oct; 32(44):5233-40. PubMed ID: 23178495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and verification of a three-dimensional (3D) breast cancer tumor model composed of circulating tumor cell (CTC) subsets.
    Anil-Inevi M; Sağlam-Metiner P; Kabak EC; Gulce-Iz S
    Mol Biol Rep; 2020 Jan; 47(1):97-109. PubMed ID: 31583566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of activated leukocyte cell adhesion molecule in breast cancer. Predictability of the response to taxane-free chemotherapy].
    Kilic E; Milde-Langosch K; Müller V; Wirtz R; Ihnen M
    Pathologe; 2008 Nov; 29 Suppl 2():347-52. PubMed ID: 18810438
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer.
    Bertucci F; Finetti P; Viens P; Birnbaum D
    Cancer Lett; 2014 Dec; 355(1):70-5. PubMed ID: 25218596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in ER, PR and HER2 receptors status after neoadjuvant chemotherapy in breast cancer.
    Yang YF; Liao YY; Li LQ; Xie SR; Xie YF; Peng NF
    Pathol Res Pract; 2013 Dec; 209(12):797-802. PubMed ID: 24183366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.